Group 1: New Stock Offerings - Two new stocks are set to be offered for subscription this week: Jiyuan Group on the Shanghai Stock Exchange and Shanda Electric on the ChiNext board, both starting on Monday [1][3] Group 2: Jiyuan Group Overview - Jiyuan Group is the largest global supplier of HMB raw materials and a core supplier of high-quality glucosamine and chondroitin sulfate [2][5] - The company focuses on the research and development of dietary nutritional supplements and has over 20 years of experience in the global dietary supplement industry [4] - Jiyuan Group's revenue for 2022, 2023, and 2024 is projected to be 947 million, 892 million, and 1 billion yuan respectively, with net profits of 142 million, 160 million, and 174 million yuan [6] Group 3: Jiyuan Group's Fundraising Plans - The funds raised will be invested in the construction of a nutritional health raw material production base, expansion of production lines, and a technology innovation center [7] Group 4: Shanda Electric Overview - Shanda Electric is a high-tech enterprise focused on the research and development of intelligent products for power systems, with a strong presence in smart grid monitoring technology [8] - The company has established good relationships with major power companies and has a market presence across 22 provinces, 5 autonomous regions, and 4 municipalities in China [8] - Shanda Electric's revenue for 2022, 2023, and 2024 is projected to be 478 million, 549 million, and 658 million yuan respectively, with net profits of 77 million, 103 million, and 127 million yuan [9] Group 5: Shanda Electric's Fundraising Plans - The funds raised will be used for projects related to power grid fault analysis, smart equipment production, and the development of intelligent charging stations for new energy vehicles [9] Group 6: Recent Market Trends - Recently listed new stocks have shown strong performance, with a notable example being Tongyu New Materials, which saw a 128% increase on its first trading day [11]

Core Viewpoint - The company, Jiyuan Group, is launching an IPO with a share price of 10.88 yuan and a price-to-earnings ratio of 25.51, which is lower than the industry average of 27.69, indicating a potential investment opportunity in the dietary supplement sector [1]. Company Overview - Jiyuan Group specializes in the research, innovation, and industrialization of dietary nutritional supplements, providing original and customized nutritional raw materials and formulations globally [1]. - The company is a leading developer and market promoter of HMB nutrients, holding multiple core patents and extensive clinical data for its myHMB® brand [1]. Financial Performance - The projected revenues for Jiyuan Group are approximately 9.47 billion yuan in 2022, 8.92 billion yuan in 2023, and 10.02 billion yuan in 2024, with net profits of about 1.44 billion yuan, 1.61 billion yuan, and 1.75 billion yuan respectively [2]. - Total assets are expected to grow from 924.46 million yuan in 2022 to 1,186.02 million yuan in 2024, while equity attributable to shareholders is projected to increase from 599.85 million yuan to 937.21 million yuan over the same period [3]. - The company's debt-to-asset ratio is expected to decrease from 34.30% in 2022 to 20.23% in 2024, indicating improved financial stability [3]. Research and Development - Jiyuan Group invests approximately 4.96% of its revenue in research and development, reflecting its commitment to innovation in the dietary supplement industry [3].